Literature DB >> 17388107

Key protein alterations associated with hyperdynamic cardiac function: insights based on proteomic analysis of the protein phosphatase 1 inhibitor-1 overexpressing hearts.

Anand Pathak1, Brent Baldwin, Evangelia G Kranias.   

Abstract

Transgenesis based on organ specific gene expression has provided the basis to elucidate the functional role of proteins for the past 15 years. Using this technology, we showed that inhibition of the protein phosphatase 1, by its constitutively active inhibitor-1, significantly increases cardiac contractility and calcium handling. To uncover protein changes accompanying the chronic increases in cardiac function of these transgenic hearts, we analyzed the cardiac proteome. Interestingly, we found significant increases in the levels of 6 proteins involved in metabolism, calcium binding and scavenging of oxido-reductive stress. These proteins were identified as: hydroxyacyl CoA dehydrogenase II, alpha subunit of the mitochondrial proton ATPase, peroxiredoxin 2, a novel EF-hand containing protein-2, annexin 5, and a previously uncharacterized cDNA. Thus, long-term cardiac specific overexpression of the protein phosphatase 1 inhibitor-1 and the associated increases in cardiac contractility appear to herald changes in a rather small number of proteins, which may reflect important compensatory adaptations in a hyperdynamic heart [corrected]

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388107

Source DB:  PubMed          Journal:  Hellenic J Cardiol        ISSN: 1109-9666


  6 in total

Review 1.  Rescuing the failing heart by targeted gene transfer.

Authors:  Yoshiaki Kawase; Dennis Ladage; Roger J Hajjar
Journal:  J Am Coll Cardiol       Date:  2011-03-08       Impact factor: 24.094

Review 2.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

3.  Potential of gene therapy as a treatment for heart failure.

Authors:  Roger J Hajjar
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

Review 4.  Gene therapy for heart failure.

Authors:  Lisa Tilemann; Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2012-03-02       Impact factor: 17.367

5.  Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte death and apoptosis.

Authors:  Wen Zhao; Guo-Chang Fan; Zhi-Guo Zhang; Arun Bandyopadhyay; Xiaoyang Zhou; Evangelia G Kranias
Journal:  Basic Res Cardiol       Date:  2008-11-22       Impact factor: 17.165

Review 6.  Gene therapy for heart failure: where do we stand?

Authors:  Charbel Naim; Armen Yerevanian; Roger J Hajjar
Journal:  Curr Cardiol Rep       Date:  2013-02       Impact factor: 2.931

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.